The Effect of Long-Term Mestranol Administration on Calcium and Phosphorus Homeostasis in Oophorectomized Women

1971 ◽  
Vol 41 (3) ◽  
pp. 233-236 ◽  
Author(s):  
J. M. Aitken ◽  
D. McKay Hart ◽  
D. A. Smith
Keyword(s):  
Parathyroid Hormone ◽  
Serum Calcium ◽  
Urinary Calcium ◽  
Calcium Excretion ◽  
Hormone Activity ◽  
Phosphorus Excretion ◽  
Calcium And Phosphorus ◽  
Urinary Phosphorus Excretion ◽  
Parathyroid Hormone Activity

1. A group of women who had undergone hysterectomy and bilateral salpingooophorectomy were studied and subsequently given either 20–40 μg of mestranol per day or a placebo for 1 year. 2. The administration of mestranol to these oophorectomized women for 1 year was associated with significant falls in serum calcium and phosphorus concentrations, a fall in urinary calcium excretion and a rise in relative urinary phosphorus excretion. 3. It is suggested that these results are consistent with an increase in sensitivity to calcitonin and that the relative hyperphosphaturia reflects a compensatory rise in parathyroid hormone activity.

Effect of calcitonin on salivary phosphorus and calcium excretion in sheep

1984 ◽  
Vol 102 (3) ◽  
pp. 365-368 ◽  
Author(s):  
T. Matsui ◽  
Y. Kanagawa ◽  
H. Yano ◽  
R. Kawashima
Keyword(s):  
Parathyroid Hormone ◽  
Cyclic Amp ◽  
Serum Calcium ◽  
Salivary Secretion ◽  
Calcium Excretion ◽  
Serum Concentrations ◽  
Serum Parathyroid Hormone ◽  
Phosphorus Excretion ◽  
Parotid Duct ◽  
Secretion Rates

ABSTRACT Three thyroidectomized sheep were infused intravenously with porcine calcitonin at a rate of 30 mi.u./h per kg and three sham-operated sheep were infused with vehicle for 5 h. Saliva was collected from the left parotid duct by cannulation for 10 min in every hour. Salivary secretion rates were not changed in either thyroidectomized or sham-operated sheep throughout the experiment. Before the infusion, salivary phosphorus excretion was less in thyroidectomized sheep than in sham-operated animals. Calcitonin infusion increased salivary phosphorus excretion and decreased serum phosphorus concentrations in thyroidectomized sheep. Vehicle infusion did not affect salivary phosphorus excretion in sham-operated sheep. Serum concentrations and salivary excretion of calcium were decreased by calcitonin infusion into thyroidectomized sheep but were not changed in sham-operated sheep infused with vehicle. Calcitonin infusion increased serum parathyroid hormone concentrations in thyroidectomized sheep after the decrease of serum calcium concentrations. However, vehicle infusion did not affect serum parathyroid hormone concentrations in sham-operated sheep. There was little change of cyclic AMP excretion during the experiment in either thyroidectomized or sham-operated sheep. It is concluded that calcitonin increases salivary phosphorus excretion in sheep. J. Endocr. (1984) 102, 365–368

Update – Kalziumstoffwechsel

2019 ◽  
Vol 144 (16) ◽  
pp. 1125-1132
Author(s):  
Christof Schöfl
Keyword(s):  
Parathyroid Hormone ◽  
Calcium Concentration ◽  
Urinary Calcium ◽  
Urinary Calcium Excretion ◽  
Free Calcium ◽  
Calcium Excretion ◽  
Calcium Balance ◽  
Stomach Pain ◽  
Free Calcium Concentration

AbstractA finely balanced control system keeps the extracellular calcium concentration within narrow limits. Disorders of calcium metabolism are often based on altered parathormone levels. Symptoms are not always clear, sometimes they are even missing: the more it is important to know possible associated diseases. The author presents basics, current diagnostics and concrete therapy options. Central hormone for the regulation of the calcium balance is the parathyroid hormone. With decreasing calcium, PTH leads to an increase in extracellular free calcium concentration in three ways. The classic symptoms of pHPT (polyuria, polydipsia, “stone, leg, and stomach pain”) are rare now, as the condition is diagnosed much earlier. Treatment of choice in all symptomatic patients with pHPT is surgery. FHH and pHPT are both characterized by hypercalcaemia and increased parathyroid hormone. The differential diagnosis of urinary calcium excretion, which is usually lower in FHH but normal or elevated in pHPT, is crucial. In primary hypoparathyroidism, parathyroid failure interferes with calcium homeostasis at a central location. Consequences are hypocalcaemia, hyperphosphatemia and lack of active vitamin D. Due to increased urinary calcium excretion, patients with ADH are at high risk for kidney stones, nephrocalcinosis and the development of renal insufficiency. Recently, rhPTH 1-84 has been available for the treatment of hypoparathyroidism. However, long-term data is still lacking to provide a safe indication, considering potential effects and side effects.

Fluoride Therapy and Parathyroid Hormone Activity in Osteoporosis

1990 ◽  
Vol 79 (3) ◽  
pp. 233-238 ◽  
Author(s):  
T. C. B. Stamp ◽  
P. W. Saphier ◽  
N. Loveridge ◽  
C. R. Kelsey ◽  
A. J. Goldstein ◽  
...  
Keyword(s):  
Alkaline Phosphatase ◽  
Parathyroid Hormone ◽  
Sodium Fluoride ◽  
Serum Alkaline Phosphatase ◽  
Biologically Active ◽  
Calcium Balance ◽  
Hormone Activity ◽  
Cross Sectional ◽  
Parathyroid Hormone Activity

1. To determine the relationships between parathyroid hormone activity and long-term sodium fluoride therapy in osteoporosis, cytochemical bioassays (for biologically active parathyroid hormone) were performed in 22 osteoporotic control patients and in 18 patients after 15 ± 10 months of treatment (60 mg of sodium fluoride daily). Ten patients were studied longitudinally by repeated metabolic balances and were therefore common to both groups. All patients were receiving mineral supplements. 2. Cross-sectional data showed a fourfold mean increase in biologically active parathyroid hormone on fluoride treatment (P < 0.005) together with a 51% increase in serum alkaline phosphatase (P < 0.005). Longitudinal data showed, in addition, a significant increase in the calcium balance of 2.4 ± 1.2 (sem) mmol daily (P < 0.05) and the development of a positive phosphorus balance (P < 0.02). 3. Fluoride-treated patients were then analysed in two groups according to the level of biologically active parathyroid hormone. Thirty-two per cent of values were above the upper limit of normal (18 pg/ml). The mean serum alkaline phosphatase level in this group showed no elevation above that of the control patients, the overall rise being accounted for entirely by patients with normal levels of biologically active parathyroid hormone. High levels of biologically active parathyroid hormone were also associated with relative hypophosphataemia (P < 0.01), relative hypercalciuria (P < 0.05) and an increased urine/faecal calcium ratio (P < 0.025). 4. Results show that long-term fluoride and calcium therapy increase biologically active parathyroid hormone in osteoporosis and that excessive parathyroid hormone activity may account for certain features of the refractory state.

DECREASED PARATHYROID FUNCTION IN HYPERTHYROIDISM: INTERRELATIONSHIPS BETWEEN SERUM PARATHYROID HORMONE, CALCIUM-PHOSPHORUS METABOLISM AND THYROID FUNCTION

1977 ◽  
Vol 84 (3) ◽  
pp. 566-575 ◽  
Author(s):  
Leif Mosekilde ◽  
Merete Sanvig Christensen
Keyword(s):  
Parathyroid Hormone ◽  
Urinary Excretion ◽  
Serum Calcium ◽  
Elevated Serum ◽  
Serum Levels ◽  
Urinary Calcium ◽  
Albumin Concentration ◽  
Parathyroid Function ◽  
Calcium Phosphorus ◽  
Calcium And Phosphorus

ABSTRACT Serum immunoreactive parathyroid hormone (S-iPTH) was measured together with serum and urinary calcium and phosphorus in 45 hyperthyroid patients in order to assess parathyroid function. Serum calcium and phosphorus were increased and positively correlated to the degree of hyperthyroidism. The prevalence of hypercalcaemia was 51.1 % using serum calcium values corrected for individual variations in serum albumin concentration compared to 15.6% using the uncorrected calcium values. S-iPTH was decreased and inversely correlated to serum calcium (corrected). Subnormal levels of S-iPTH were found in 28.9 % of the patients. The urinary excretion of calcium and phosphorus was increased and positively correlated to the degree of hyperthyroidism. The tubular reabsorption of calcium (TRCa %) was decreased, positively correlated to S-iPTH and inversely correlated to serum calcium. Increased mobilisation of bone mineral in hyperthyroidism is suggested mainly to be responsible for the elevated serum levels and increased urinary excretion of calcium and phosphorus and for the decreased parathyroid function.

ENDOCRINE EFFECTS OF LITHIUM:

1978 ◽  
Vol 88 (3) ◽  
pp. 528-534 ◽  
Author(s):  
C. Christiansen ◽  
P. C. Baastrup ◽  
P. Lindgreen ◽  
I. Transbøl
Keyword(s):  
Parathyroid Hormone ◽  
Primary Hyperparathyroidism ◽  
Serum Calcium ◽  
Lithium Treatment ◽  
Serum Magnesium ◽  
Endocrine Effects ◽  
Manic Depressive ◽  
Depressive Patients ◽  
Immunoreactive Parathyroid Hormone

ABSTRACT Ninety-six manic-depressive patients were studied during long-term lithium treatment. Highly significant elevations were observed respecting the levels of serum immunoreactive parathyroid hormone (P < 0.001) as well as the protein-corrected levels of serum calcium (P < 0.001) and serum magnesium (P <0.001), thus indicating a state of 'primary' hyperparathyroidism. The patients as a group had normophosphataemia and normophosphatasia supporting the impression of a rather mild state of biochemical hyperparathyroidism.

scholarly journals Safety and Efficacy of 5 Years of Treatment With Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism

2019 ◽  
Vol 104 (11) ◽  
pp. 5136-5147 ◽  
Author(s):  
Michael Mannstadt ◽  
Bart L Clarke ◽  
John P Bilezikian ◽  
Henry Bone ◽  
Douglas Denham ◽  
...  
Keyword(s):  
Serum Calcium ◽  
Urinary Calcium ◽  
Open Label ◽  
Oral Calcium ◽  
Efficacy Outcome ◽  
Open Label Extension ◽  
Calcium Phosphorus ◽  
Safety Parameters ◽  
Turnover Markers

Abstract Context Conventional hypoparathyroidism treatment with oral calcium and active vitamin D is aimed at correcting hypocalcemia but does not address other physiologic defects caused by PTH deficiency. Objective To evaluate long-term safety and tolerability of recombinant human PTH (1-84) [rhPTH(1-84)]. Design Open-label extension study; 5-year interim analysis. Setting 12 US centers. Patients Adults (N = 49) with chronic hypoparathyroidism. Intervention(s) rhPTH(1-84) 25 or 50 µg/d initially, with 25-µg adjustments permitted to a 100 µg/d maximum. Main Outcome Measure(s) Safety parameters; composite efficacy outcome was the proportion of patients with ≥50% reduction in oral calcium (or ≤500 mg/d) and calcitriol (or ≤0.25 µg/d) doses, and albumin-corrected serum calcium normalized or maintained compared with baseline, not exceeding upper limit of normal. Results Forty patients completed 60 months of treatment. Mean albumin-corrected serum calcium levels remained between 8.2 and 8.7 mg/dL. Between baseline and month 60, levels ± SD of urinary calcium, serum phosphorus, and calcium-phosphorus product decreased by 101.2 ± 236.24 mg/24 hours, 1.0 ± 0.78 mg/dL, and 8.5 ± 8.29 mg2/dL2, respectively. Serum creatinine level and estimated glomerular filtration rate were unchanged. Treatment-emergent adverse events (AEs) were reported in 48 patients (98.0%; hypocalcemia, 36.7%; muscle spasms, 32.7%; paresthesia, 30.6%; sinusitis, 30.6%; nausea, 30.6%) and serious AEs in 13 (26.5%). At month 60, 28 patients (70.0%) achieved the composite efficacy outcome. Bone turnover markers increased, peaked at ∼12 months, and then declined to values that remained above baseline. Conclusion Treatment with rhPTH(1-84) for 5 years demonstrated a safety profile consistent with previous studies and improved key biochemical parameters.

Sign in / Sign up

Export Citation Format

Share Document